Talaris raises $100M series A, reports 70% immune tolerance for allogeneic cell therapy

With a new management team at the helm, Talaris raised $100 million in a series A round Thursday and reported that FCR001 led to a 70% immune tolerance rate in a Phase II trial to induce durable immune tolerance in living donor kidney transplant recipients. The company, formerly Regenerex LLC, plans to start a Phase III trial this year of the allogeneic cell therapy.